Experimental combo therapy for tough lymphoma shows promise but trial halted early
NCT ID NCT06381830
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested a two-step treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by an infusion of CAR-T cells (a type of immune cell therapy). The goal was to see if this combination could improve response rates and delay disease progression. Only 8 patients were enrolled before the study was terminated, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cell therapy and autologous stem cell transplant
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat B-cell lymphoma who have relapsed after standard therapy.
- What could go wrong
- This was a very small, early-phase trial that was terminated, so results are limited. The approach carries serious risks, including infection and organ damage from the conditioning chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOLOGOUS STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single shot build a cancer army inside the body?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Promising CAR-T therapy trial for lymphoma withdrawn before it began
- Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
- New combo tackles tough lymphoma
- Blood test may spare some transplant patients from chemo